Spectrum Pharmaceuticals, Inc.
|$1.6 B||Market Cap|
|N/A||EBIT / EV|
|N/A||FCF / EV|
|-1.0%||3yr Avg Revenue Growth|
Business Model Diligence
We do not yet have Business Model Diligence for this stock.
|Cannot calculate EBIT / Enterprise Value, company has negative EBIT.|
|Cannot calculate Free Cash Flow / Enterprise Value, company has negative Free Cash Flow.|
|Cannot calculate Return on Invested Capital, company has negative EBIT.|
|Cannot calculate Cash Return on Invested Capital, company has negative Free Cash Flow.|
|The 3 Year Average Revenue Growth Value of -1.0% ranks as Below Average.|
|Near-term Financial Health appears to be Very Good. The Current Ratio is 5.04.|
Spectrum Pharmaceuticals, Inc. engages in the acquisition, development, and commercialization of pipeline of late-stage clinical and commercial products. It targets non-Hodgkin's lymphoma, advanced metastatic colorectal cancer, acute lymphoblastic leukemia, and multiple myeloma. It operates through the following brands: FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, EVOMELA, EOQUIN, and RenaZorb. The company was founded in December 1987 and is headquartered in Henderson, NV.
|Valvoline Inc. (VVV)|
|Procter & Gamble Company (PG)|
|McDonald's Corporation (MCD)|
|Fiat Chrysler Automobiles N.V. (FCAU)|
|Baozun Inc Sponsored ADR Class A (BZUN)|
|Vector Group Ltd. (VGR)|
|New Stocks Added!|